RNAZ · TransCode Therapeutics Inc. Common Stock
View on chartInsiders & Stakes
| DEFJ, LLC 10% Owner | ▼ Sell | Other | 14,134,481 Shares held | 8/3/2026 | View profile |
| Dudley Robert Michael Chief Executive Officer | ▲ Buy | Open Market | 180,262 Shares held | 9/28/2023 | View profile |
| Fitzgerald Thomas A Chief Financial Officer | ▲ Buy | Open Market | 56,318 Shares held | 9/28/2023 | View profile |
Transaction History
| DEFJ, LLC | ▼ Sell | Other | 11,813,859 | — | 8/3/2026 |
| DEFJ, LLC | ▼ Sell | Other | 2,020,582 | — | 8/3/2026 |
| Fitzgerald Thomas A | ▲ Buy | Open Market | 49,350 | $25K | 9/28/2023 |
| Dudley Robert Michael | ▲ Buy | Open Market | 98,000 | $50K | 9/28/2023 |
| Dudley Robert Michael | ▲ Buy | Open Market | 12,000 | $32K | 6/21/2023 |
| Dudley Robert Michael | ▲ Buy | Open Market | 6,607 | $17K | 6/20/2023 |
| Dudley Robert Michael | ▲ Buy | Open Market | 19,000 | $52K | 6/9/2023 |
| Dudley Robert Michael | ▲ Buy | Open Market | 20,000 | $23K | 9/14/2022 |
| Fitzgerald Thomas A | ▲ Buy | Open Market | 12,000 | $15K | 6/16/2022 |
| Dudley Robert Michael | ▲ Buy | Open Market | 2,000 | $4K | 5/31/2022 |
| Dudley Robert Michael | ▲ Buy | Open Market | 28,000 | $52K | 5/27/2022 |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 3, 2026
TransCode Reports Phase 1a Data for TTX-MC138
TransCode Therapeutics released updated results from its Phase 1a trial of TTX-MC138. The company reported continued disease stabilization and extended treatment duration in patients with advanced solid tumors. These findings add to the clinical evidence for the drug in heavily pretreated patients.
TransCode Reports Phase 1a Data for TTX-MC138. TransCode Therapeutics released updated results from its Phase 1a trial of TTX-MC138. The company reported continued disease stabilization and extended treatment duration in patients with advanced solid tumors. These findings add to the clinical evidence for the drug in heavily pretreated patients.